AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35250203 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 35250870 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-1 treatment
Number of subjects: 213
Study 35251038 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in GLI activity by small molecule inhibitors or shRNA-mediated knockdown of GLI1 or GLI2.
Number of subjects: 0
Study 35251315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m² in combination with everolimus
Number of subjects: 39
Study 35251320 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib + endocrine therapy (ET)
Number of subjects: 329
Study 35251346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin administered at an intermediate dose (8,000-12,000 Anti-Xa IU; once daily)
Number of subjects: 407
Study 35251346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin administered at a prophylactic dose (≤4,500 Anti-Xa IU; once daily)
Number of subjects: 407
Study 35251346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin (both doses)
Number of subjects: 407
Study 35252369 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid Body Rotation (RBR)
Number of subjects: 17
Study 35252369 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwall Fibrosis (MWF)
Number of subjects: 17
Study 35252369 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro brain natriuretic peptide (NT-proBNP)
Number of subjects: 17
Study 35253296 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive counselling with easily accessible and approachable healthcare professionals
Number of subjects: 28
Study 35253296 — intervention group
Group type: EXPERIMENTAL
Intervention: Information before rectal cancer surgery
Number of subjects: 28
Study 35253296 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling after surgery for low anterior resection syndrome
Number of subjects: 28
Study 35253296 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professionals' understanding of major low anterior resection syndrome
Number of subjects: 28
Study 35253361 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide 6.25 mg/kg IV q6h from the day prior to conditioning through day +21
Number of subjects: 25
Study 35253361 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide 6.25 mg/kg IV q6h
Number of subjects: 25
Study 35253443 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antithrombotic agents
Number of subjects: 5324
Study 35253450 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 0
Study 35253450 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher standardized nadir CD4 T-cell count
Number of subjects: 0
Study 35253450 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of standardized TNF-α
Number of subjects: 0
Study 35254001 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphine-phosphonium gold(I) complex
Number of subjects: 0
Study 35254001 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphine gold(I) complex
Number of subjects: 0
Study 35254270 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated feedback
Number of subjects: 71
Study 35254270 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated+clinician feedback
Number of subjects: 71
Study 35254270 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated feedback+social network feedback
Number of subjects: 71
Study 35254270 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 71
Study 35254385 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant PFHPert (palbociclib, trastuzumab, and pertuzumab)
Number of subjects: 28
Study 35254415 — intervention group
Group type: EXPERIMENTAL
Intervention: Taminadenant (80-640 mg, orally, twice a day)
Number of subjects: 25
Study 35254415 — intervention group
Group type: EXPERIMENTAL
Intervention: Taminadenant (80-640 mg, orally, twice a day) with spartalizumab (400 mg, i.v., every 4 weeks)
Number of subjects: 25
Study 35254415 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 35254416 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB086550 (a small-molecule PD-L1 inhibitor)
Number of subjects: 0
Study 35254525 — intervention group
Group type: EXPERIMENTAL
Intervention: CT acquisition protocols before harmonization
Number of subjects: 0
Study 35254525 — intervention group
Group type: EXPERIMENTAL
Intervention: CT acquisition protocols after harmonization
Number of subjects: 0
Study 35254525 — intervention group
Group type: EXPERIMENTAL
Intervention: LongComBat harmonized features
Number of subjects: 0
Study 35254961 — intervention group
Group type: EXPERIMENTAL
Intervention: TMDp patients
Number of subjects: 54
Study 35254961 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic approach
Number of subjects: 54
Study 35255097 — intervention group
Group type: EXPERIMENTAL
Intervention: ZIKV-exposed infants
Number of subjects: 0
Study 35255097 — intervention group
Group type: COMPARATOR
Intervention: ZIKV unexposed infants
Number of subjects: 0
Study 35255140 — intervention group
Group type: COMPARATOR
Intervention: CoronaVac vaccine (2 doses, 8-12 weeks before enrollment)
Number of subjects: 193
Study 35255199 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral pre-exposure prophylaxis (PrEP)
Number of subjects: 130
Study 35255536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (n = 49)
Number of subjects: 74
Study 35255536 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 25)
Number of subjects: 74
Study 35255536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 74
Study 35255710 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidonic acid (AA) metabolites measured by mass spectroscopy
Number of subjects: 805
Study 35255750 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem use before the regulatory change
Number of subjects: 15851
Study 35255750 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem use after the regulatory change
Number of subjects: 15851
Study 35255964 — intervention group
Group type: EXPERIMENTAL
Intervention: INSTI-based regimen (13 subjects)
Number of subjects: 19
Study 35255964 — intervention group
Group type: EXPERIMENTAL
Intervention: INSTI-based regimen
Number of subjects: 19
Study 35255964 — intervention group
Group type: COMPARATOR
Intervention: NNRTI-based regimen (6 subjects)
Number of subjects: 19
Study 35255976 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational rehabilitation programs (VRP)
Number of subjects: 146
Study 35256010 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal chiropractic care for chronic low back pain (10-week course, mean visits 4.5)
Number of subjects: 40
Study 35256018 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed implementation strategy for active learning
Number of subjects: 2
Study 35256018 — intervention group
Group type: COMPARATOR
Intervention: Usual support
Number of subjects: 2
Study 35256316 — intervention group
Group type: EXPERIMENTAL
Intervention: MF-directed monotherapy (hydroxyurea or ruxolitinib)
Number of subjects: 205
Study 35256316 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 205
Study 35256495 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive smoking exposure (mother only)
Number of subjects: 518
Study 35256495 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive smoking exposure (father only)
Number of subjects: 518
Study 35256495 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive smoking exposure (both parents)
Number of subjects: 518
Study 35256495 — intervention group
Group type: COMPARATOR
Intervention: No passive smoking exposure
Number of subjects: 518
Study 35256525 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment
Number of subjects: 3027
Study 35256525 — intervention group
Group type: COMPARATOR
Intervention: No lipid-lowering treatment
Number of subjects: 3027
Study 35256693 — intervention group
Group type: EXPERIMENTAL
Intervention: Thionamide anti-thyroid drug (titration dosing regimen)
Number of subjects: 0
Study 35256844 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment preferences based on avoiding severe nerve damage and longer progression-free survival (PFS)
Number of subjects: 126
Study 35256844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost implications on treatment preferences
Number of subjects: 126
Study 35256844 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver preferences
Number of subjects: 126
Study 35256844 — intervention group
Group type: EXPERIMENTAL
Intervention: BWS exercise results
Number of subjects: 126
Study 35257522 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 1036
Study 35257579 — intervention group
Group type: EXPERIMENTAL
Intervention: Potent small-molecule inhibitors of AAK1 (specific dosage and duration not mentioned)
Number of subjects: 0
Study 35257639 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined isoflavone compound (CIC)
Number of subjects: 0
Study 35257644 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 0
Study 35257800 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac plexus radiosurgery with a single 25-Gy fraction
Number of subjects: 18
Study 35257800 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac plexus radiosurgery
Number of subjects: 18
Study 35257874 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaler technology
Number of subjects: 0
Study 35257874 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard inhaler)
Number of subjects: 0
Study 35257949 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/30 mg once daily with pembrolizumab 200 mg every 3 weeks
Number of subjects: 24
Study 35257974 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD with SMART Pass algorithm
Number of subjects: 322
Study 35257974 — intervention group
Group type: COMPARATOR
Intervention: S-ICD without SMART Pass algorithm
Number of subjects: 322
Study 35257974 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD in patients with ARVC
Number of subjects: 322
Study 35257974 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD in general
Number of subjects: 322
Study 35258437 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 Critical Illness Survivors
Number of subjects: 0
Study 35258437 — intervention group
Group type: COMPARATOR
Intervention: Non-COVID-19 Critical Illness Survivors
Number of subjects: 0
Study 35258461 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated family planning (FP) and maternal, newborn, and child health (MNCH) services including capacity strengthening of health care providers, counseling of women and girls, sustained provision of supplies, community engagement, and use of health data in decision-making.
Number of subjects: 0
Study 35258476 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation (PPV)
Number of subjects: 49
Study 35258782 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncardiogenic ischemic stroke patients
Number of subjects: 2558
Study 35258782 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension, dyslipidemia, abnormal HbA1c, intracranial artery stenosis, carotid plaque
Number of subjects: 2558